Analytical Data
-
Gene name
SSX6
- Application
-
Alternative Names
SSX6P; SSX6; Putative Protein SSX6
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q7RTT6
-
Expression Region
1-188 aa
-
AA Sequence
MNGDDAFAKR PRDDAKASEK RSKAFDDIAK YFSKEEWEKM KFSEKISCVH MKRKYEAMTK LGFNVTLSLF MRNKRATDSQ RNDSDNDRNR GNEVERPQMT FGRLQRIIPK IMPEKPAEEG SDSKGVPEAS GPQNDGKKLC PPGKASSSEK IHERSGPKRG KHAWTHRLRE RKQLVIYEEI SDPEEDDK
-
Molecular Weight
21.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SSX6 (synovial sarcoma X chromosome 6) is a member of the SSX gene family, which is predominantly expressed in testicular germ cells and various tumors, particularly synovial sarcoma. Its role as a cancer/testis antigen has garnered significant interest in cancer immunotherapy, as SSX6 is not typically expressed in normal adult tissues, making it an attractive target for therapeutic strategies that aim to elicit an immune response specifically against tumor cells. Research on SSX6 has focused on its potential as a biomarker for cancer diagnosis, prognosis, and treatment, particularly in malignancies where standard therapies are limited. Studies have shown that SSX6 can induce T-cell responses, indicating its utility in designing personalized cancer vaccines or adoptive T-cell therapies. Additionally, understanding the molecular mechanisms regulating SSX6 expression and activity could provide insights into tumor biology and the development of more effective treatment modalities. Ongoing research aims to elucidate the role of SSX6 in tumorigenesis and its interaction with the immune system, contributing to advancements in targeted cancer immunotherapy approaches.
